News Post

The FDA reportedly identified quality-control issues at a Neuralink animal lab shortly after Elon Musk said the startup was cleared to start human tests

Business InsiderBusiness Insider · 8m
The FDA reportedly identified quality-control issues at a Neuralink animal lab shortly after Elon Musk said the startup was cleared to start human tests

The US Food and Drug Administration (FDA) has reportedly found issues with record-keeping and quality controls for animal experiments at Elon Musk's Neuralink facility in California. The issues, identified between June 12 and 22, 2023, were not deemed significant enough for regulatory action by the FDA. Neuralink, which aims to implant brain chips to enable human-computer interaction, had announced FDA approval for human trials in May 2023. The company's Texas site did not have the same problems. This is not the first time Musk's ventures have faced regulatory scrutiny, with previous reports of mistreatment of animals and workplace safety concerns.

Comments

Download the medial app to read full posts, comements and news.